In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
J-C YangP-R Hsueh

Abstract

The minimum inhibitory concentrations (MICs) of 330 nonduplicate Helicobacter pylori isolates to nemonoxacin, tigecycline, and eight other antimicrobial agents were determined by using the agar dilution method. Sequencing the quinolone resistance-determining regions (QRDRs) in the gyrA gene of these isolates was also performed. Resistance to clarithromycin showed an increasing trend during the ten-year study period and was highest (38%) in 2005. Tigecycline had potent in vitro activities against all isolates, with an MIC(90) of 0.06 μg/ml. Among the quinolones tested, nemonoxacin (MIC(50) of 0.12 μg/ml and MIC(90) of 0.25 μg/ml) and gemifloxacin had one to two-fold better in vitro activities than ciprofloxacin, levofloxacin, and moxifloxacin. Among the nine isolates (2.7%) with levofloxacin resistance, four (44.4%) were also resistant to metronidazole, three (33.3%) to clarithromycin, and two (22.2%) to amoxicillin. Isolates with levofloxacin resistance exhibited one or two of three amino acid alterations (Ser-70, Asn-87, and Asp-91) involved in QRDRs in the gyrA gene. A double mutation at Ser70Cys and Asn87Ile had a higher level of resistance. The results of this study suggest a potentially useful role of nemonoxacin and tigec...Continue Reading

References

Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·H W Minehart, A F Chalker
Sep 15, 2005·The Journal of Antimicrobial Chemotherapy·Jung Mogg KimIn Sung Song
Sep 14, 2006·The American Journal of Gastroenterology·Enrico C NistaAntonio Gasbarrini
Oct 18, 2006·Antimicrobial Agents and Chemotherapy·Erik GlockerManfred Kist
Jul 5, 2007·The American Journal of Gastroenterology·William D CheyUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Sep 15, 2007·Gastroenterology·Nimish Vakil, Francis Megraud
Sep 10, 2009·Antimicrobial Agents and Chemotherapy·Heather J AdamGeorge G Zhanel
Oct 1, 2009·Journal of Gastroenterology and Hepatology·K Ming FockUNKNOWN Second Asia-Pacific Conference
Dec 18, 2009·Expert Review of Anti-infective Therapy·Lyudmila Boyanova, Ivan Mitov

❮ Previous
Next ❯

Citations

Oct 8, 2014·Pharmaceutical Patent Analyst·Sukhbir K Shahid
Jul 4, 2012·Current Opinion in Pharmacology·Karen Bush
Jul 7, 2015·Journal of Digestive Diseases·Peng BaiYu Ding
Dec 25, 2013·Antimicrobial Agents and Chemotherapy·Kobkul ChotikanatisMargaret R Hammerschlag
Feb 11, 2019·Biotechnology Letters·Gobinath ChandrakasanNorberto Chavarría-Hernández
Mar 4, 2014·Expert Review of Anti-infective Therapy·Chung-Chih LaiPo-Ren Hsueh
Jun 24, 2017·Middle East Journal of Digestive Diseases·Fariborz Mansour-GhanaeiFarahnaz Joukar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.